EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral Combined Probiotics Clostridium butyricum and Akkermansia muciniphila Inhibits the Progression of 4T1 Breast Cancer by Activating Bcl‐2/Bax Pathway

Xiaowei Li, Dengxiong Hua, Daoyan Wu, Wei Hong, Yingqian Kang, Lei Tang, Qin Yang, Xinxin Wang, Boyan Li, Renmin Li, Zhenghong Chen, Guzhen Cui iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Xiaowei Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province,…. Hauptthemen laut MEDLINE: Probiotics, bcl-2-Associated X Protein, Proto-Oncogene Proteins c-bcl-2, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, 111 Project, Guizhou Health Commission Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer is the most common malignant tumor among women. Recent studies have found that gut probiotics and their metabolic products play a significant role in activating the immune system, reshaping the tumor microenvironment, and inhibiting cancer progression.

Methods

We established a 4T1 tumor‐bearing mice model and analyzed the proportions of CD4 + T and CD8 + T cells in the spleen using flow cytometry and immunohistochemistry. The expression levels of TNF‐α, IL‐6, and IL‐10 were measured by enzyme‐linked immunosorbent assay. Hematoxylin–eosin staining was used to observe the tumor morphology. Selective protein blotting and quantitative real‐time PCR were used to analyze the expression of Bax, Bcl‐2, and Caspase‐3. Cell proliferation was evaluated using the MTT assay, and apoptosis was detected by flow cytometry.

Results

The results indicated that oral administration of CB and AKK possesses the capability to inhibit the progression of 4T1 breast cancer; however, the combined treatment with both strains (CB‐AKK) exhibited significantly superior effects compared to each individual strain. Further mechanistic analysis revealed that the CB‐AKK combination could activate the antitumor immunity in mice and reshape the tumor microenvironment. Additionally, it was found that the live bacteria and their metabolites derived from CB‐AKK could inhibit cell proliferation and promote tumor apoptosis by activating the Bcl‐2/Bax signaling pathway.

Conclusion

This study is the first to demonstrate that orally administered live bacteria CB‐AKK can inhibit the progression of 4T1 breast cancer, providing a promising new strategy for the development of innovative biotherapies for breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Probioticsbcl-2-Associated X ProteinProto-Oncogene Proteins c-bcl-2Breast NeoplasmsClostridium butyricumAkkermansiaAnimalsFemaleMiceApoptosisSignal TransductionCell Line, TumorAdministration, OralCell ProliferationDisease ProgressionMice, Inbred BALB CHumansTumor Microenvironment

Stichwörter der Autor:innen

Akkermansia muciniphilaClostridium butyricumBcl‐2/Bax signaling pathwayapoptosisbreast cancerprobiotics

Substanzen

bcl-2-Associated X ProteinProto-Oncogene Proteins c-bcl-2Bax protein, mouseBcl2 protein, mouse

Autor:innen und Institutionen

  • Key Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.
  • Joint Laboratory of Helicobacter Pylori and Intestinal Microecology of Affiliated Hospital of Guizhou Medical University, Guiyang, China.
  • Guizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control, Guiyang, China.
  • Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China.
  • School of Public Health, Guizhou Medical University, Guiyang, China.
  • Standard Testing Group Co., Ltd., Qingdao, China.

ORCID-Profile: Guzhen Cui

Förderung

  • National Natural Science Foundation of China
  • 111 Project
  • Guizhou Health Commission Project
  • High-Level Innovation Talent Project of Guizhou
  • Science and Technology Research Project for Guizhou
  • Excellent Young Talent Program of Guizhou Medical University
  • Guizhou Key Laboratory
  • Scientists Workstation Guizhou Province

Zitieren

APA

Li, X., Hua, D., Wu, D., Hong, W., Kang, Y., Tang, L., Yang, Q., Wang, X., Li, B., Li, R., Chen, Z., & Cui, G. (2025). Oral Combined Probiotics Clostridium butyricum and Akkermansia muciniphila Inhibits the Progression of 4T1 Breast Cancer by Activating Bcl‐2/Bax Pathway. Cancer Medicine. https://doi.org/10.1002/cam4.70987

Vancouver

Li X, Hua D, Wu D, Hong W, Kang Y, Tang L, et al. Oral Combined Probiotics Clostridium butyricum and Akkermansia muciniphila Inhibits the Progression of 4T1 Breast Cancer by Activating Bcl‐2/Bax Pathway. Cancer Medicine. 2025. doi:10.1002/cam4.70987

BibTeX
@article{Li2025,
  author = {Li, Xiaowei and Hua, Dengxiong and Wu, Daoyan and Hong, Wei and Kang, Yingqian and Tang, Lei and Yang, Qin and Wang, Xinxin and Li, Boyan and Li, Renmin and Chen, Zhenghong and Cui, Guzhen},
  title = {Oral Combined Probiotics Clostridium butyricum and Akkermansia muciniphila Inhibits the Progression of 4T1 Breast Cancer by Activating Bcl‐2/Bax Pathway},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70987}
}
Kostenlos starten →